Apalutamide plus androgen-deprivation therapy (ADT) improved outcomes in patients with non-metastatic castration-resistant prostate cancer (nmCRPC).
The aim of this multicenter study was to generate real-world data from nmCRPC patients treated with ADT plus apalutamide.
